First oral GLP-1 treatment for type 2 diabetes approved
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
List view / Grid view
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
The British Pharmacopoeia and United States Pharmacopeia partnership is to be formalised to strengthen the quality of medicines and public health.
The cannabidiol-based treatment EPIDYOLEX has been granted marketing authorisation from the European Commission.
Health authorities in the Democratic Republic of Congo are planning to use a second vaccine to treat the Ebola virus.
A treatment for anaemia associated with chronic kidney disease in dialysis patients has been approved in Japan.
Darmerica LLC is voluntarily recalling two lots of quinacrine dihydrochloride due to a label mix-up.
The government of an Indian province and a US company have teamed together in an initiative to deliver medications to remote regions using drones, which should begin next year.
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.
A Biologics License Application and priority review has been approved by the FDA for an investigational Ebola vaccine.
Lanadelumab, a preventive treatment for hereditary angioedema, has been recommended as a cost-effective use of NHS resources.
Pharmaceutical Manufacturing Research Services has filed a lawsuit against the FDA after it rejected its application for opioids with updated labelling and appearance, meant to discourage misuse.
A new initiative has already collaboratively reviewed applications for two oncology drugs, allowing for simultaneous decisions in three countries.
The UK Medicine and Healthcare products Regulatory Agency has released a revision to its standards for ensuring high quality of biologic products.
Orphan Drug Designation has been given to bispecific antibody candidate, GBR 1342, for the treatment of multiple myeloma.
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.